As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering over the festive period. We saw data suggesting that sickle cell patients could soon see an approved gene therapy in what is an increasingly crowded market.  

Battlegrounds for Car-T therapies, menin inhibitors and bispecifics all saw action, with the share prices of the main contenders punished or rewarded accordingly. As ever, ASH has set the deal-making stage for JP Morgan in January – good news for the investors who’ve been looking for something to be confident about for most of the year. 



Toxicity challenges in the bispecific space
Why fast production is not the answer to Car-T’s problems
The late-stage multiple myeloma therapy on its way to the regulator
A next-gen BTK inhibitor that can put patients who relapse on Imbruvica back into remission
Will there finally be more options for patients in immune thrombocytopenia?